NCT00691405 - A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

215

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

May 31, 2004

Study Completion Date

May 31, 2004

Conditions

COPD

Interventions

DRUG

Arformoterol tartrate inhalation solution

Arformoterol 5 mcg BID

DRUG

Arformoterol tartrate inhalation solution

Arformoterol 15 mcg BID

DRUG

Arformoterol tartrate inhalation solution

Arformoterol 25 mcg BID

DRUG

Placebo

Placebo inhalation solution BID

DRUG

Arformoterol tartrate inhalation solution

Arformoterol 15 mcg QD

DRUG

Arformoterol tartrate inhalation solution

Arformoterol 25 mcg QD

DRUG

Arformoterol tartrate inhalation solution

Arformoterol 50 mcg QD

DRUG

Placebo

Placebo inhalation solution QD

Trial Locations (31)

Unknown

Encinitas

Long Beach

Brandon

Cleawater

Fort Lauderdale

Jacksonville

Port Orange

West Palm Beach

Austell

Topeka

Marrero

New Orleans

Opelousas

McCook

Princeton

Hickory

Statesville

Winston-Salem

Columbus

Eugene

Medford

Pittsburgh

Charleston

Columbia

Simpsonville

Spartanburg

Austin

San Antonio

Renton

Spokane

Tacoma

All Listed Sponsors

lead

Sumitomo Pharma America, Inc.

INDUSTRY